ApoB (apolipoprotein B) is a protein found on the surface of every cholesterol-carrying particle capable of driving atherosclerosis, including LDL, VLDL, and Lp(a). Measuring ApoB directly counts how many of these particles are in your blood, while standard LDL cholesterol (LDL-C) only estimates the total amount of cholesterol those particles are carrying, not how many particles there are. This distinction, count versus content, is at the center of why ApoB is increasingly considered the more accurate cardiovascular risk marker of the two, and why major cardiology guidance has started endorsing it directly rather than treating it as a niche, specialist-only test. The 2019 ESC/EAS guideline sets ApoB targets of below 100 mg/dL at moderate risk, 80 at high risk and 65 at very high risk.
- ApoB directly counts atherogenic particles. LDL-C only estimates their total cholesterol content, an indirect proxy.
- Two people can have identical LDL-C but meaningfully different ApoB, and different real-world cardiovascular risk.
- The 2019 ESC/EAS guideline endorses ApoB outright as a more accurate risk measure than LDL-C or non-HDL cholesterol. US guidance treats it as a risk-enhancing factor rather than a primary target.
- Below 100 mg/dL is a reasonable ApoB target, below 65 mg/dL is an optimized, aggressive result.
Why particle count matters more than particle content
Atherosclerosis, the buildup of plaque in artery walls that eventually drives most heart attacks and strokes, begins when cholesterol-carrying particles lodge themselves in the arterial wall and trigger an inflammatory cascade. Critically, it's the number of particles that get lodged that matters for this process, not how much cholesterol each individual particle happens to be carrying. A single large, cholesterol-rich particle and a single small, cholesterol-poor particle are roughly equally capable of starting this process once they're stuck in the artery wall. Each counts as one event, whatever cargo it was carrying.
This is exactly where LDL-C's blind spot comes from. LDL-C is calculated (traditionally estimated via the Friedewald equation, though increasingly measured more directly in modern labs) as the total cholesterol mass carried across all your LDL particles combined. If you have many small, cholesterol-poor particles, a pattern sometimes associated with insulin resistance and metabolic dysfunction, your LDL-C can look deceptively normal or even good, while your actual particle count, and therefore your actual atherosclerotic risk, is elevated. The reverse happens too. Fewer, larger, cholesterol-rich particles can produce a higher LDL-C reading while representing a lower particle count, and lower risk than the raw number suggests.
Why the number of particles matters more than their cargo
ApoB sidesteps this by counting particles directly. Essentially every atherogenic particle carries exactly one ApoB molecule on its surface, whether it is LDL, VLDL or Lp(a). Count the ApoB, count the particles.
ApoB vs. LDL cholesterol, side by side
| ApoB | LDL Cholesterol (LDL-C) | |
|---|---|---|
| What it measures | Number of atherogenic particles | Total cholesterol mass in LDL particles |
| Includes Lp(a) and VLDL | Yes | No |
| Can be normal with elevated risk | Rarely | Yes, with small dense LDL patterns |
| Guideline endorsement | ESC/EAS as a primary target; AHA/ACC as a risk-enhancing factor | Long-standing, traditional standard |
| Typical availability | Requires a specific request or advanced panel | Included in every standard lipid panel |
Comparison of what each marker measures and how it is used clinically.
What counts as a good ApoB level?
For ApoB, measured in milligrams per decilitre, the 2019 ESC/EAS guideline sets targets by risk category. Which category you are in is a clinical judgement, based on your existing conditions and overall risk profile rather than on the ApoB number itself.
| Risk category | ApoB target |
|---|---|
| Moderate risk | Below 100 mg/dL |
| High risk | Below 80 mg/dL |
| Very high risk | Below 65 mg/dL |
Targets from the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Risk category is a clinical judgement based on existing conditions and overall risk profile.
For reference, standard LDL-C clinical categories, still widely used and still meaningful even as ApoB gains ground:
| Category | LDL-C |
|---|---|
| Optimal | Below 100 mg/dL |
| Near optimal | 100 – 129 mg/dL |
| Borderline high | 130 – 159 mg/dL |
| High | 160 – 189 mg/dL |
| Very high | 190 mg/dL and above |
Widely used conventional clinical categories rather than the recommendation of a single named body.
Order both. LDL-C is what most treatment decisions and drug trials are still built around, and ApoB is what to trust when the two point in different directions.
ApoB interpreter
Enter your ApoB to see it against the guideline targets. A standard lipid panel won’t include this unless you ask for it.
Why clinical guidelines are shifting toward ApoB
The 2019 ESC/EAS dyslipidaemia guideline concluded outright that ApoB is a more accurate measure of cardiovascular risk than either LDL-C or non-HDL cholesterol, and that it can be measured more accurately than either. That is a meaningful shift for a field that relied on LDL-C as the primary treatment target for decades. US guidance has moved more cautiously: the 2018 AHA/ACC guideline treats ApoB as a risk-enhancing factor rather than a primary target.
Two lines of evidence sit behind the European position. A 2019 mendelian randomisation analysis across 654,783 participants found that the benefit of lowering triglycerides or LDL-C was proportional to the absolute change in ApoB, which points at ApoB as the thing actually doing the damage rather than a correlate of it. A separate 2021 analysis in The Lancet Healthy Longevity used outcomes in first-degree relatives and found genetically higher ApoB associated with roughly two years of life lost, with the association strengthening once LDL-C and triglycerides were accounted for.
The 2024 UK Biobank discordance analysis is the practical version of the same point. When ApoB and LDL-C disagree about someone, ApoB is the one that tracks the outcome. That test matters because it isolates the two markers in exactly the cases where they would otherwise be indistinguishable, rather than leaning on how well they correlate across a general population.
None of which makes LDL-C useless. It remains a reasonable predictor for most people, and it is what decades of cardiovascular outcome trials used to establish treatment targets and drug effectiveness. That is an enormous evidence base, and ApoB is still catching up on sheer volume of outcome data.
But if your risk picture does not add up, ApoB is the more informative next step. Early heart disease in the family despite normal LDL-C. Metabolic syndrome. Insulin resistance alongside cholesterol numbers that look fine.
How to get ApoB tested
ApoB isn't included in a standard lipid panel by default. It usually needs either a specific request to your doctor, or an advanced lipid panel that includes it alongside the standard markers. It's an ordinary blood draw, with no preparation beyond the usual fasting guidance, and results come back in mg/dL on the same turnaround as a standard cholesterol panel.
Because it isn't yet routine everywhere, availability and insurance coverage vary. Some doctors order it readily for anyone with cardiovascular risk factors. Others need asking, particularly if your standard panel looks unremarkable. Direct-to-consumer labs have made it easier to get without a referral, though reading the result against your family history, blood pressure and other risk factors is still worth doing with a clinician rather than reacting to the number alone.
How to lower ApoB
The levers overlap heavily with those for cholesterol generally. Cut saturated fat. Increase soluble fibre, which binds cholesterol in the gut and reduces absorption. Train aerobically. Lose weight where relevant.
Visceral fat deserves singling out. It is specifically linked to the small, dense particle pattern that makes ApoB and LDL-C diverge in the first place, so reducing it closes the gap between the two numbers rather than just lowering both.
If ApoB stays elevated despite consistent effort, several drug classes have strong evidence behind them: statins, ezetimibe and PCSK9 inhibitors among them. Which one suits you depends on your risk category and how much reduction you need. That is a conversation with a doctor, not something to settle from a website.
Limitations
ApoB isn't a complete cardiovascular risk picture on its own, any more than LDL-C is. It's one strong input among several, alongside blood pressure, inflammatory markers like hs-CRP, family history and metabolic health.
Why two identical ApoB results can mean different things
It also can't tell you which particles it counted. LDL, VLDL and Lp(a) all contribute equally to the number. That matters, because a high ApoB driven mostly by Lp(a) is largely genetic and barely responds to lifestyle, while one driven by LDL particles from diet responds well. Same number, different problem.
Someone whose ApoB is elevated should know their Lp(a) before concluding that diet and training will bring the number down. Roughly one in five people have Lp(a) at or above 125 nmol/L, and in those people a meaningful share of the ApoB count is fixed.
Cost and availability are a real limit for some people. Technically it's a simple blood test, but it isn't yet as cheap or as widely stocked as a standard panel, and insurance coverage varies with your documented risk factors.
Common misconceptions
"If my LDL-C is normal, I don't need to worry about ApoB." This is the exact scenario where ApoB adds the most. Normal LDL-C with elevated ApoB, often a small dense particle pattern, means real cardiovascular risk that a standard panel misses entirely. Nothing on that panel would flag it, sometimes for years.
"ApoB replaces the need for a standard lipid panel." It complements one. Standard panels still report HDL and triglycerides, which ApoB doesn't capture. Each catches something the other misses.
"High ApoB always means the same treatment approach." ApoB counts several particle types together, so the right intervention depends on which of them is driving your number. That needs the fuller lipid picture and a doctor, not the ApoB figure alone.
"ApoB is only relevant for people who already have heart disease." Its value is arguably greatest before that. Someone with no diagnosis and borderline cholesterol numbers is exactly where a standard panel leaves the most uncertainty, and where an ApoB result can change the conversation while there is still time.
How to act on an ApoB result
Most popular health writing still leans on standard LDL-C, the decades-old default. The case for asking for ApoB instead is narrow and specific: when the two disagree, the discordance research shows ApoB is the more reliable predictor.
Request it alongside your next standard lipid panel, particularly if your cholesterol numbers are ambiguous or there is early heart disease in your family. Read the result against the benchmark table above, and alongside your other cardiovascular markers rather than in isolation.
If body composition is the bigger lever for you, start there. ApoB and standard cholesterol markers both tend to improve as a by-product of the same changes to weight and diet.
Longevity Coach IQ tracks ApoB alongside your full cardiovascular picture, showing how it compares to your standard lipid panel.
Sources
Key references for the claims on this page. Where a figure is attributed to a specific study or body, it is named here.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 2020;41(1):111-188. The source of the ApoB targets above, and the guideline that concluded ApoB is a more accurate risk marker than LDL-C or non-HDL-C. DOI
- Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA, 2019;321(4):364-373. Mendelian randomisation across 654,783 participants, finding the benefit of lowering triglycerides or LDL-C is proportional to the absolute change in ApoB. DOI
- Richardson TG, Wang Q, Sanderson E, et al. Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives. The Lancet Healthy Longevity, 2021;2(6):e317-e326. The lifespan analysis referenced above. DOI
- Sniderman AD, Dufresne L, Pencina KM, et al. Discordance among apoB, non-HDL-C and LDL-C: the UK Biobank analysis. European Heart Journal, 2024;45(27):2410-2418. The discordance evidence, confirming ApoB outperforms both alternatives when they disagree. DOI
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR guideline on the management of blood cholesterol. Circulation, 2019;139(25):e1082-e1143. The US guideline position, which treats ApoB as a risk-enhancing factor rather than a primary target. DOI
Frequently asked
What is ApoB?
A protein on the surface of every atherogenic particle (LDL, VLDL, Lp(a)). Measuring it counts particles directly rather than estimating cholesterol content.
What is a good ApoB level?
Below 100 mg/dL is reasonable, below 80 mg/dL is strong, below 65 mg/dL is an optimized, aggressive result.
Why is ApoB considered better than LDL cholesterol?
LDL-C measures total cholesterol content, not particle count, and it's particle count that actually drives arterial plaque formation. Two people can share an LDL-C but have very different real risk.
Do I need to ask my doctor specifically for ApoB testing?
Often yes, it isn't always included in a standard lipid panel by default, particularly if your standard cholesterol numbers look unremarkable but other risk factors are present.
Does a statin lower ApoB the same way it lowers LDL-C?
Generally yes, statins reduce both, though the exact proportional reduction can differ somewhat, which is part of why some clinicians now track ApoB directly during treatment rather than relying on LDL-C alone to judge whether therapy is working.
Is ApoB testing covered by insurance?
Coverage varies by plan and by whether documented cardiovascular risk factors are on file, worth checking directly with your insurer or asking your doctor's office about likely out-of-pocket cost before ordering it.